Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces its appointment as Financial PR & Investor Relations advisor to AIM listed Tissue Regenix Group plc, the regenerative medical devices company. The team at Walbrook will manage the Company’s communications with the financial media, research analysts and non-institutional investors, including new and existing private investors.
Tissue Regenix Group plc (AIM: TRX) is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn-out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specialises in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.
For more information visit the Company’s website: www.tissueregenix.com
Paul McManus, Founder and Managing Director of Walbrook PR, commented: “We are thrilled to be working with Tissue Regenix and I look forward to working with CEO, Daniel Lee, CFO, David Cocke, and the Board to raise the profile of the Company and their exciting, patented portfolio of regenerative products.”
For further information please contact:
About Walbrook PR: www.walbrookpr.com
Walbrook PR was founded in April 2009 by Paul McManus and focuses on providing high quality Financial PR and Investor Relations to Small Cap and AIM listed companies.
Walbrook PR is ranked 2nd in the AIM Adviser Rankings guide and is ranked 7th by total number of Stock Market listed clients. Walbrook acts for 56 listed companies (mainly AIM) across a wide mix of sectors and is ranked 1st in Healthcare and 4th in Technology, by number of AIM clients.
Walbrook PR prides itself on having a strong reputation for working with growing UK Small Cap and AIM listed companies; a proven IR offering, which focuses on the Private Client Investment Management community and the retail investment community; and on having a proactive, hands-on approach from a committed team with full ownership of the business.